03 August 2018
Microgen, a Russian biotech company which is part of the Natsimbio holding firm, has completed the development of a new combinatory vaccine for measles, rubella and parotitis (mumps). The Vactrivir is expected to protect people against the three dangerous diseases simultaneously.
The Vactrivir is reported to have been successfully tested at the preclinical and clinical trial stages, proving its safety and therapeutic efficacy. Following 42 days of observation after the vaccine was administered studies have shown good tolerance in patients and a level of safety high enough for both adults and children.
“By this moment we have put together all the documents required to get the new drug candidate registered in Russia. With its level of safety and efficacy we can also talk of high export potential for the solution,” Microgen CEO Kirill Gaidash said.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024